ES2058596T3 - Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso. - Google Patents

Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.

Info

Publication number
ES2058596T3
ES2058596T3 ES89830544T ES89830544T ES2058596T3 ES 2058596 T3 ES2058596 T3 ES 2058596T3 ES 89830544 T ES89830544 T ES 89830544T ES 89830544 T ES89830544 T ES 89830544T ES 2058596 T3 ES2058596 T3 ES 2058596T3
Authority
ES
Spain
Prior art keywords
nervous system
therapeutic treatment
carnitine derivatives
degenerative alterations
degenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89830544T
Other languages
English (en)
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2058596T3 publication Critical patent/ES2058596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REVELA EL USO DE COMPONENTES DE FORMULA GENERAL: DONDE : Y ES HIDROGENO, METRIL O AMINO, Y R ES UN GRUPO ALQUIL SUSTITUIDO O NO SUSTITUIDO ELEGIDO ENTRE METIL, ETIL, 1-METILPROPIL, ISOBUTIL, MERCAPTOMETIL Y 3-GUANIDINOPROPIL Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LO MISMO, PARA EL TRATAMIENTO DE LAS ALTERACIONES DEGENERATIVAS DEL SISTEMA NERVIOSO. LOS COMPUESTOS PUEDEN SER ADMINISTRADOS ORAL O PARENTERALMENTE.
ES89830544T 1988-12-27 1989-12-13 Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso. Expired - Lifetime ES2058596T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8848717A IT1224842B (it) 1988-12-27 1988-12-27 Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso

Publications (1)

Publication Number Publication Date
ES2058596T3 true ES2058596T3 (es) 1994-11-01

Family

ID=11268228

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89830544T Expired - Lifetime ES2058596T3 (es) 1988-12-27 1989-12-13 Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.

Country Status (8)

Country Link
US (1) US5043355A (es)
EP (1) EP0376899B1 (es)
JP (1) JP2828293B2 (es)
AT (1) ATE92316T1 (es)
DE (1) DE68908145T2 (es)
ES (1) ES2058596T3 (es)
IT (1) IT1224842B (es)
ZA (1) ZA899802B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
DK0951909T4 (da) 1998-03-19 2011-01-24 Sigma Tau Ind Farmaceuti Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
JP5047507B2 (ja) * 2005-09-30 2012-10-10 昭和電工株式会社 カルニチン誘導体及びその塩、皮膚外用剤ならびに化粧料
US7842726B2 (en) * 2005-09-30 2010-11-30 Showa Denko K.K. Carnitine derivative, salt thereof, external skin preparation and cosmetic material
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
US20200129464A1 (en) * 2018-10-29 2020-04-30 Lonza Inc. Method and Composition for Increasing the Bioavailability of Carnitine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1208753B (it) * 1986-07-02 1989-07-10 Sigma Tau Ind Farmaceuti L-amminoacil derivati della l-carnitina, procedimento per la loro preparazione e composizioni farmaceutiche ad attivita' epatoprotettrice che li contengono
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche

Also Published As

Publication number Publication date
ATE92316T1 (de) 1993-08-15
US5043355A (en) 1991-08-27
DE68908145T2 (de) 1993-11-25
EP0376899A3 (en) 1991-09-18
EP0376899A2 (en) 1990-07-04
ZA899802B (en) 1990-11-28
JPH02207020A (ja) 1990-08-16
IT8848717A0 (it) 1988-12-27
DE68908145D1 (de) 1993-09-09
JP2828293B2 (ja) 1998-11-25
HK1005849A1 (en) 1999-01-29
IT1224842B (it) 1990-10-24
EP0376899B1 (en) 1993-08-04

Similar Documents

Publication Publication Date Title
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
MX9704777A (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y composiciones que los contienen.
DK164937C (da) Analogifremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater eller farmaceutisk acceptable syreadditionssalte deraf samt 1-alkyl-2-aminotetralinderivater til anvendelse som udgangsmateriale i fremgangsmaaden
PA8432901A1 (es) Compuestos de piridilpirrol
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
ECSP941122A (es) Derivados de 5-arilindoles
SE9702564D0 (sv) New compounds
ES2108717T3 (es) Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
MX9301197A (es) Derivados de indol.
AR004229A1 (es) Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos
IT1224842B (it) Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
ES2071663T3 (es) Analogo de fluoxetina.
SE9702563D0 (sv) Compounds
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
MX9401080A (es) Compuestos heteroaromaticos.
ES2124256T3 (es) Arilmorfolina, preparacion y uso.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
ES2156212T3 (es) Derivados de azabicicloheptano n-substituidos como neurolepticos, etc.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 376899

Country of ref document: ES